University of Oxford – Confidence in Concept 2019
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
People |
ORCID iD |
Publications
Memarian Sorkhabi M
(2021)
Pulse-Width Modulation-based TMS mimics effects of conventional TMS on human primary motor cortex
Sorkhabi M
(2020)
Temporally Interfering TMS: Focal and Dynamic Stimulation Location
Mead AJ
(2022)
A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.
in Therapeutic advances in hematology
Soltan A
(2021)
Rapid triage for COVID-19 using routine clinical data for patients attending hospital: development and prospective validation of an artificial intelligence screening test
in The Lancet Digital Health
Memarian Sorkhabi M
(2021)
Paralleling insulated-gate bipolar transistors in the H-bridge structure to reduce current stress.
in SN applied sciences
| Description | Advancing Oligonucleotide Therapeutics |
| Amount | £951,725 (GBP) |
| Funding ID | BB/W003902/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | BMS Fellowship |
| Amount | £660,607 (GBP) |
| Organisation | Bristol-Myers Squibb |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2021 |
| End | 08/2022 |
| Description | Decision-support for individualised risk assessment of fetal health during labour: preventing fetal brain damage and death by utilising large, routinely collected datasets of cardiotocography and clinical risk factors |
| Amount | £1,118,105 (GBP) |
| Funding ID | NIHR202117 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2021 |
| End | 04/2024 |
| Description | Developing Raman micro-spectroscopy to determine the OXPHOS /glycolysis status of patient tumours |
| Amount | £10,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Development of a CRISPR treatment for USH2A-associated retinitis pigmentosa |
| Amount | £60,000 (GBP) |
| Organisation | The Royal College of Surgeons of Edinburgh |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Direct Costs for Devices |
| Amount | £25,000 (GBP) |
| Organisation | The Magstim Company Limited |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Doctoral studentship |
| Amount | £30,000 (GBP) |
| Organisation | University of Oxford |
| Department | Magdalen College Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | EPSRC Healthcare Technology |
| Amount | £600,699 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC Collaboration Grant |
| Amount | £200,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MRC Unit programme grant |
| Amount | £2,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | MSD Bridging salary scheme |
| Amount | £33,403 (GBP) |
| Organisation | University of Oxford |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | RNA editing-mediated uORF disruption - molecular therapies for haploinsufficiency disorder |
| Amount | £74,629 (GBP) |
| Organisation | Medical and Life Sciences Translational Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Smart electroceuticals for neurological disorders (SEND) |
| Amount | £192,417 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2022 |
| End | 05/2025 |
| Description | TransNAT: NATA |
| Amount | £8,000,000 (GBP) |
| Funding ID | MR/X008029/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Title | xTMS: Flexible Transcranial Magnetic Stimulation System |
| Description | The xTMS system is a programmble transcranial magnetic stimulator device. The xTMS system enables more control on the electric field pulse shape than conventional TMS device. The pTMS2 system enables PWM electric field pulse with control over the pulse shape, duration, directionality, pulse type such as mono-phasic, bi-phasic and polyphasic. It can be used in single pulse mode or repetitive TMS mode. The xTMS system requires a stimulation coil to deliver the magnetic stimulation. Brief stimuli of an electromagnetic field are applied to the neural tissues with current-carrying treatment coils. The fast-changing field induces electrical currents within the neurons and modulates cell activity. Using the xTMS device, it is possible to change the stimulus waveform and polarity of each pulse in the pulse train. It is intended for use by, or under the supervision of, a medical practitioner or investigator who has knowledge about the principles of TMS, physiology and potential side effects of TMS. It's the user's responsibility to design and validate safeness of their stimulation protocols. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2021 |
| Provided To Others? | Yes |
| Impact | We have completed the first clinical study using the xTMS approach, and have now initiated a second study at Oxford. For this year, we are expanding to collaborations at King's College, London and Cambridge University. The studies are in publication review. Note that this project includes a collaboration with Magstim Ltd in Whitland Wales, who is supplying TMS coils for researchers to use. |
| Description | xTMS collaboration |
| Organisation | The Magstim Company Limited |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The economic cost of neurological disorders exceeds £100B/yr in the UK alone, and new technologies that might provide therapeutic solutions are increasingly attractive. This project will deliver a versatile scientific instrument for non-invasive actuation of the nervous system using Transcranial Magnetic Stimulation (TMS). The new system, MAGNETO, closes key performance gaps in stimulation capability that enables new therapeutic potential for neurological disorders. We have already secured lead clinical users at Oxford, King's College, UCL and Cambridge to apply the tool to explore novel therapies for high-need areas in stroke, epilepsy, motor systems and neuropsychiatry (depression, anxiety), respectively. Their insights will guide the design process and maximise translation probability. With the guidance of these lead-users, MAGNETO will enable: 1) the ability to prescribe novel patterns of stimulation enabled with our unique technology, 2) the modelling of the magnetic coupling to the neural interface for exploring optimal pulse parameters, and 3) real-time control capability for automated exploration of pulse shape and patterns. The key deliverable will be a fully-integrated prototype medical device suitable for first-in-human studies. The expectation is that these studies focus on the clinical translation of therapies for major neurological disorders. |
| Collaborator Contribution | Magstim has provided direct funds for the transistors and power electronic assemblies for the prototypes to support Oxford, Cambridge and King's. For in-kind, they have provided TMS coils and electronics, design guidance, regulatory guidance, and human factors feedback throughout the project. |
| Impact | Publications are noted in the publications tab. Our outcome for the xTMS tool is noted in the research platforms/instrumentation support tab. |
| Start Year | 2020 |
| Title | Optimisation of control of reactive circuit for generating electromagnetic pulses |
| Description | Covers a method of optimising digital pulsing sequencing to a series of power electronic drives to produce the desired magnetic stimulation pulses at the TMS coils. |
| IP Reference | |
| Protection | Patent / Patent application |
| Year Protection Granted | |
| Licensed | No |
| Impact | not known |
| Title | Systems and methods for measuring a response of a subject to an event. |
| Description | Systems and methods for measuring a response of a subject to an event. |
| IP Reference | |
| Protection | Patent / Patent application |
| Year Protection Granted | |
| Licensed | Commercial In Confidence |
| Impact | n/k |
| Company Name | ORFONYX BIO LTD |
| Description | A spin-out company has been formed (Orfonyx Bio Ltd) founded by ROBERTS (and others) which aims to commericialise uORF-related findings and generate novel molecular medicines for current unmet clinical needs. This biotech company will serve as an ideal vehicle for licensing novel IP to, and further progressing the pre-clinical/clinical development of novel therapies arising from this grant. |
| Year Established | 2022 |
| Impact | Is currently operating at the Oxford BioEscalator (£5 million seed raise) as of late November 2022 |
| Description | American Association of Cancer Research Myeloid Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: "Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML)" Co-authors: Alberto Risueño, PhD, Wendy L. See, PhD, Courtney D. DiNardo, MD, MSCE, Hartmut Döhner, MD, Eytan Stein, MD5, Amir T. Fathi, MD6, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath, Lynn Quek, MD PhD, Thomas Prebet, MD, PhD, Anita K. Gandhi, PhD9 and Maroof Hasan, MD |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://ash.confex.com/ash/2022/webprogram/Session22525.html |
| Description | Belgian Academy of Sciences |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Paresh VYAS (Professor of Haematology at the University of Oxford, Oxford, UK) : Paresh Vyas : Clonal Cell Heterogeneity in Tissues With Aging Alters Function: Using Whole Genome Sequencing and Single Cell Sequencing To Study These Processes In Blood Cells As An Exemplar Ruud Delwel (Professor "Molecular Leukemogenesis", Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands): How good genes can become Evil in leukemia Steven O. Smith (Professor - Director of Structural Biology, Department of Biochemistry and Cell Biology Stony Brook, NY USA) : Lessons from brain-derived amyloid fibril structures from Alzheimer's Disease patients https://www.youtube.com/watch?v=GjyrzYunfPU See also: https://www.facebook.com/probramedecine/ |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://www.youtube.com/watch?v=GjyrzYunfPU |
| Description | Conference / Exposition: American Association of Cancer Research Myeloid Meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Title: "Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML)" Co-authors: Alberto Risueño, PhD, Wendy L. See, PhD, Courtney D. DiNardo, MD, MSCE, Hartmut Döhner, MD, Eytan Stein, MD5, Amir T. Fathi, MD6, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath, Lynn Quek, MD PhD, Thomas Prebet, MD, PhD, Anita K. Gandhi, PhD9 and Maroof Hasan, MD |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://ash.confex.com/ash/2022/webprogram/Session22525.html |
| Description | Conference / Exposition: University of Texas South Western |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | PLENARY SESSION 8: CELL AND IMMUNE TARGETING IN MYELOID MALIGNANCIES SESSION CHAIR: PARESH VYAS, UNIVERSITY OF OXFORD, OXFORD, UNITED KINGDOM 12:00 P.M.-1:45 P.M. Talk title: "Graft versus Leukemia (GvL): Identification and characterization of alloreactive antigens and cognate T cell responses in acute myeloid leukemia" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.aacr.org/meeting/acute-myeloid-leukemia-and-myelodysplastic-syndrome/program/ |
| Description | EHA (European Haematology Association) Annual Meeting. |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | TOLERABILITY AND EFFICACY OF THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY MAGROLIMAB COMBINED WITH AZACITIDINE IN FRONTLINE PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA: PHASE 1B RESULTS Dr. Naval G Daver Author(s): Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard Larson, Adam Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany Tanaka, Terrence Bradley, Deepa Jeyakumar, Eunice Wang, Guan Xing, Mark Chao, Giri Ramsingh, Camille Renard, Indu Lal, Joshua Zeidner, David Sallman (Abstract release date: 05/26/22) EHA Library. G Daver N. 06/10/2022; 356996; S132 |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://library.ehaweb.org/eha/2022/eha2022-congress/356996/naval.g.daver.tolerability.and.efficacy.... |
| Description | ESH (European Society of Haematology) Treatment of Leukaemias (Virtual) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | (Latest session from 2022 not recorded. Earlier talk from 2019 recorded at URL provided below): The AML Global Portal were delighted to speak to Paresh Vyas, University of Oxford, Oxford, UK, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Paresh Vyas: When do you use single-cell MRD assessment in AML? Paresh Vyas discusses the role of measurable residual disease (MRD) monitoring in informing clinical practice and reviews different approaches such as next-generation sequencing (NGS), flow cytometry and single-cell measurement of disease. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://aml-hub.com/medical-information/esh-2019-or-when-do-you-use-single-cell-mrd-assessment-in-am... |
| Description | Experts in Residence meeting with Aptus Clnical |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Industry/Business |
| Results and Impact | The project team engaged with Aptus Clinical via the experts in residence scheme. Our research team received very valuable advice on investor deck preparation and how to prepare for industry engagement activities. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with Magstim |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The research team is engaged iwith Magstim, a potencial disctributor for the technology developed under the project. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Industry engagement activities with Philips and Huntleigh Healthcare |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Industry/Business |
| Results and Impact | The research team has enaged with two major market leaders, Philips and Huntliegh Healthcare, with regards to market access and commercialisation of the Fit for Labor test. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Myeloid Workshop (Cincinnati, USA) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Since 1995, the Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia has offered a highly successful presentation series from approximately 40-50 renowned national and international researchers and clinicians. The goal of these biennial workshops is to bring together investigators with expertise in complementary aspects of stem cell biology and myelopoiesis - from normal myelopoiesis to myeloid leukemias and myelodysplastic/myeloproliferative syndromes. Basic researchers and clinician investigators from both sides of the Atlantic, Australia and Japan come together biennially to discuss their latest findings in a close and informal setting. The workshop brings together scientists with expertise in normal and abnormal hematopoiesis and clinicians who treat leukemia/MDS/MPD patients and also have active research programs in these diseases. Participants achieve a better understanding of critical steps/factors that regulate hematopoiesis, their impact in leukemogenesis, and potential relevance in clinical settings. Although there are other workshops and meetings dedicated to understanding the regulation of hematopoiesis or clinical advances in leukemia, this workshop uniquely brings together both clinicians and scientists in a relaxed forum. Speakers: (See URL) |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://myeloidmeeting.org |
| Description | University of Texas South Western |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | PLENARY SESSION 8: CELL AND IMMUNE TARGETING IN MYELOID MALIGNANCIES SESSION CHAIR: PARESH VYAS, UNIVERSITY OF OXFORD, OXFORD, UNITED KINGDOM 12:00 P.M.-1:45 P.M. TITLE: "Graft versus Leukemia (GvL): Identification and characterization of alloreactive antigens and cognate T cell responses in acute myeloid leukemia" |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://www.aacr.org/meeting/acute-myeloid-leukemia-and-myelodysplastic-syndrome/program/ |
| Description | iWAL (International Workshop on Acute Leukemia) Workshop (Nice, France): iWAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | iwAL 2022 Session V: Mechanisms of resistance to targeted therapies in AML Tuesday Dec 06, 2022 The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year's meeting. In this podcast, Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, and Carsten Müller-Tidow, MD, University Hospital Heidelberg, Heidelberg, Germany, discuss mechanisms of resistance to targeted therapies in AML, and the role of epigenetics. |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://vjhemonc.podbean.com/e/iwal-2022-session-v-mechanisms-of-resistance-to-targeted-therapies-in... |